Vivus Weight-Loss Pill Qnexa Wins Backing of FDA Advisory Panel
February 27, 2012, 4:03 PM ESTBy Anna Edney
Feb. 22 (Bloomberg) -- Vivus Inc.’s weight-loss pill Qnexa won the backing of a U.S. advisory panel as the company seeks to gain approval for the first obesity drug in 13 years.
The Food and Drug Administration advisers voted 20-2 today Qnexa’s benefits outweigh its risks at a meeting at agency headquarters in Silver Spring, Maryland. The FDA isn’t required to follow the panel’s recommendation.
--Editors: Andrew Pollack, Angela Zimm
To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net
To contact the editor responsible for this story: Adriel Bettelheim at abettelheim@bloomberg.net
